Oncimmune Share Discussion Threads

[homebrewruss] 09/6/2021 09:10

Recording and Q&A now available from yesterday hTTps://www.investormeetcompany.com/investor/meeting/fy2021-end-of-year-trading-update

[pugugly] 08/6/2021 17:13

IMC Useful presentation with useful revene figures - Has been recorded and well worth a listen (imo) if a holder or a potential investor

[trotterstrading] 08/6/2021 15:21

Clear takeover target. Premium offer coming soon IMHO

[homebrewruss] 08/6/2021 11:48

Latest proactive interview hTTps://www.youtube.com/watch?v=ManVu25RJ2w&ab_channel=Proactive and ONC also presenting on investor meet later today at 4.30pm hTTps://www.investormeetcompany.com/oncimmune-holdings-plc/register-investor

[someuwin] 08/6/2021 11:13

N+1 Singer Trading update reaffirms positive outlook A comprehensive FY’21 (May Y/E) trading statement touts a strong FY’21 outturn in line with our expectations that shows 8x topline growth, building strength in the ImmunoINSIGHTS service business and sets the tone for future upgrades. We leave estimates unchanged, but believe forecasts are prudently pitched with risk to the upside. Notably Investors should take confidence in that management believes that, eight days into the new financial year and a strong start to FY’22, it has visibility on up to 50% of our current FY’22 ImmunoINSIGHTS revenue estimate (£9.4m) and has used today’s statement to reiterate confidence in meeting expectations and delivering maiden profitability in FY’22. Refreshing our valuation analysis implies an intrinsic value of 271p, we reiterate Oncimmune as a Best Idea for 2021...

[trotterstrading] 08/6/2021 08:15

Huge growth story unfolding here, I'm expecting 100% share price growth from here within 12 months

[waterloo01] 08/6/2021 07:15

Agree positive update and good to see NHS work picking up.

[someuwin] 08/6/2021 07:13

Trading Update. All looks v positive to me. New contracts to be signed before end August... "The ImmunoINSIGHTS pipeline of qualified commercial opportunities has continued to grow throughout FY21 and currently stands at more than 160. A number of these opportunities are in late stage legal documentation and, as a consequence, the Company expects to sign these new contracts in Q1 FY22. These studies have been programmed into the Company's forward production schedule, which entails identifying and assigning the resources required to deliver each contract. Of particular note in this schedule are two contracts for major pharmaceutical companies which represent substantial follow-on validation contracts."

[someuwin] 28/5/2021 07:43

("Oncimmune" or the "Company") Notice of FY21 Trading Update Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, announces that it will issue a trading update for the year ended 31 May 2021 on 8 June 2021. Analyst and investor presentations Dr Adam M Hill, Chief Executive Officer and Matthew Hall, Chief Financial Officer will host an online presentation for analysts at 11:30am BST on 8 June 2021. For registration details please contact Alexander Davis of FTI Consulting at [e-mail] or 020 3727 1000. Dr Adam M Hill and Matthew Hall will also host a live presentation on Investor Meet Company at 4:30pm BST on 8 June 2021 which will be open to all existing Oncimmune shareholders and potential new investors. Access to Investor Meet Company is free and interested parties are invited to register their attendance on the following link: https://www.investormeetcompany.com/oncimmune-holdings-plc/register-investor Investors who already follow Oncimmune Holdings plc on the Investor Meet Company platform will automatically be invited. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9:00am BST the day before the meeting or at any time during the live presentation.

[rambutan2] 18/5/2021 03:11

Noted that Cizzle Bio (CIZ) listed on the main mkt last fri, would appear to be very early stage (ie many years and many fund raising t/c) but aims to develop its blood test for early stage lung cancer. EarlyCDT-Lung gets the briefest of mentions on pg30. htTp://bouldopportunities.com/wp-content/uploads/2021/04/259313-Project-Balham-Prospectus-LOCKED1.pdf

[someuwin] 17/5/2021 15:32

Immunodiagnostic Systems Holdings PLC (LSE:IDH) bid at 50% premium. Surely only a matter of time before Immunodiagnostics group Oncimmune gets bought out?

[someuwin] 12/5/2021 08:04

Look at the chart. Great buying opportunity before next leg up.

[hatfullofsky] 11/5/2021 19:41

Have to work on my timing, bought in yesterday !!!!

[someuwin] 05/5/2021 11:30

Can buy £2k worth. But not £3k.

[someuwin] 05/5/2021 09:40

N + 1 Singer... Oncimmune Holdings (ONC LN) Life Sciences Current price* 238.0p China EarlyCDT rights returned Oncimmune is to reacquire the China and Hong Kong rights to the EarlyCDT product portfolio from Genostics. The decision was made to provide strategic optionality removing a potential conflict that may have existed if Oncimmune were to access the US capital markets. The immediate financial impact of removing EarlyCDT Lung royalties in China is modest, and we have decreased our revenue estimates by 2.8% and 4.9% in FY’22 and FY’23, respectively. This decision leaves the door open for future value-creating partnerships in China, but importantly, our investment hypothesis, where we anticipate strong growth and commercial traction for the ImmunoINSIGHTS platform, remains unchanged. We continue to view Oncimmune as a Best Idea for 2021, and the next scheduled update is a post-period end trading statement expected in early June...

[trotterstrading] 05/5/2021 08:34

Sounds very bullish!

[someuwin] 05/5/2021 08:22

Sounds like the next news is very close... "We are delighted that Genostics has agreed to continue to participate in Oncimmune's success as a shareholder, and Oncimmune looks forward to progressing its market access plans imminently."

[someuwin] 05/5/2021 07:56

Zeus Capital Oncimmune ONC LN Biotechnology Reacquisition of IP and distribution rights for Chinese lung cancer test Oncimmune has reacquired IP and distribution rights for its lung cancer diagnostic (EarlyCDT®) that has been recalibrated for enhanced accuracy in Asian populations. Trials are due to complete in H1 2021, with regulatory filing to follow shortly afterwards. We would expect the company to be in advanced discussions with a new licensee/ distributor or acquirer of the geographically-specific test, and that a new licensing agreement or divestment will be net value accretive. We maintain our positive outlook for Oncimmune, based on expectations of strong revenue growth and profitability. Valuation and current forecasts are under review pending an update by a new analyst. Oncimmune has announced that it is reacquiring the IP and distribution rights for its EarlyCDT® lung cancer diagnostic in the Peoples Republic of China and Hong Kong, originally licensed to the Genostics Company Limited in January 2018. As part of the original deal Genostics made a £10m equity investment in Oncimmune. Genostics currently holds than less than a 5% share in Oncimmune. The cost of reacquisition has not been disclosed, and as such are likely to be relatively nonmaterial (i.e. < £1m). Since January 2018 Oncimmune and Genostics have been developing a lung cancer test with superior performance given the high prevalence rates of EGFR +ve non-small cell lung cancer in the China and Asia-Pacific regions. The test uses an extended panel of autoantibodies to accommodate variations in the biomarkers expressed on cancer cells that are specific to Asian populations. In May 2019 Oncimmune announced that the new test had entered a new multicentre case control study, in the People’s Republic of China assessing early detection of lung cancer, study approximately 1,000 early lung cancers at five leading academic health centres across China. The study is due to complete in H1 2021, with the data for the newly validated panel used to support approval of the test by Chinese regulators (the China National Medical Products Administration). Oncimmune has been actively pursuing a new licensing partner for EarlyCDT® in China, and we would be surprised if, given that regulatory filing is likely before midmid, the company was not in advanced discussions with either a new licensee, or even a potential acquirer. We would expect a new licensing agreement or divestment to be net value accretive. We note that a reduced dependency on China as part of overall corporate strategy may be beneficial given Oncimmune’s intention. Going forwards, to increase its focus on the US, both in terms of operations and capital markets. We maintain a positive outlook on the stock, although our valuation and current forecasts are currently under review pending an update by a new analyst."

[40 fathoms] 05/5/2021 07:52

Happy with this, trying to enter the China market without a major CCP backed partner is a recipe for failure. Give Genostics credit, they locked up a great product for the China market with no significant track record, they had a bash at trying to get it in to market and have come up short, I would say it was defiantly worth a shot. But the truth is a product like this will never be properly commercialized in China by a Genostics or similar. Much better to get all the IP back and then push forward with a CR or Citic group related company. If I am honest they have enough on their plate without even worrying about China. Bring on the NASDAQ !!!

[trotterstrading] 05/5/2021 07:37

Have they signalled US listing before, or is this the first reference to it?

[waterloo01] 05/5/2021 07:19

Interesting. Often returning rights is a negative but it doesn't seem to be the case here but clears a path toward a US listing.

[someuwin] 05/5/2021 07:15

5 May 2021 Oncimmune Holdings plc ("Oncimmune" or the "Company") Return of China Rights to EarlyCDT product portfolio Enables strategic optionality to support access to the US capital markets Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group , today announces that it has successfully agreed to acquire the intellectual property (IP) and distribution rights for the EarlyCDT (R) technology in the People's Republic of China (PRC) and Hong Kong (HK) from Genostics Company Limited (Genostics), allowing the Company to pursue the optimum route to market in this important territory. Since granting Genostics the exclusive rights to EarlyCDT products in the PRC and HK in January 2018, Oncimmune and Genostics have collaborated to develop a lung panel with superior performance in Greater China and Asia-Pacific, given the prevalence of EGFR-positive non-small cell lung cancer (NSCLC) in the region. The Asia-specific lung panel has been used in a multi-centre study, previously announced on 10 May 2019, and which is now due to complete in China in H1 2021. Data from this study are intended to be used to support approval by the China National Medical Products Administration (NMPA) for the use of the Asia-specific lung cancer test in the PRC. Under the agreement announced today, all material, IP, data, and goodwill will be transferred back to the Company, and Oncimmune will be paid in full for the royalties due in January 2021 under the existing Technology Licencing Agreement. In consideration, Oncimmune has agreed to pay a fixed amount for the return of the IP and distribution rights, with the majority of the value of the consideration being conditional on fixed future events. With accelerating growth of Oncimmune's ImmunoINSIGHTS business, the Company intends to explore options available to it to access the US capital markets in the near term. The termination of Oncimmune's partnership with Genostics and return of the EarlyCDT product rights to the PRC and HK markets provides Oncimmune with further strategic optionality which could support a path to the US capital markets. As part of the agreement, and as previously announced, Genostics has agreed to a lock-in of its remaining shareholding in Oncimmune (currently 4.73 per cent. of the issued share capital) for a period of 12 months from 6 May 2021, except under certain limited exceptions. Dr Adam M Hill, CEO of Oncimmune said: " We are grateful for the collaboration with Genostics and its parent company, Gene Group Holdings Ltd, over the past three years and are pleased with the progress that has been made with our Asia-specific lung panel. However, as both companies consider their future on different equity capital markets, the continuing success of the EarlyCDT product portfolio, both in and outside of PRC and HK, requires Oncimmune to own the IP and distribution rights. We are delighted that Genostics has agreed to continue to participate in Oncimmune's success as a shareholder, and Oncimmune looks forward to progressing its market access plans imminently."

[someuwin] 29/4/2021 13:39

Must be close to next leg up. £170m - Vs peer valuations of $ multi billions.

[trotterstrading] 29/4/2021 11:06

Deal news from their bulging pipeline due anytime now according to CEO recent interviews :)

[trotterstrading] 21/4/2021 12:20

Added a few more on the drop :)